Accreditation Information

Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activityfor a maximum of 1 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity


1. Describe the NCCN guidelines for Breast Cancer
2. Describe the recently published clinical trials of Breast Cancer
3. Discuss the new hypothesis of the clinical trials
4. Describe the multidisciplinary breast cancer care approach used at BMC
5. Identify a cancer on a mammogram
6. Differentiate the roles of breast conservation and mastectomy in the treatment of breast cancer patients
7. Use radiation and chemotherapy options for breast cancer patients, and select patients who are appropriate for genetic evaluation

Target Audience

Multidisciplinary clinicians who treat breast cancer patients at Boston Medical Center.

Faculty Disclosure

Fcaulty, Planning Committee and CME Administrator disclosure statement:

Michael Cassidy, Speaker and Course Director,  has no relevant financial relationships to disclose

Sakina Flint, RSS Coordination, has no relevant financial relationships to disclose

Faculty disclosure of off-label use

Faculty member does not plan on discussing unlabeled/investigational uses of a commercial product.

Faculty disclosure policy:

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.